Login
Companies $HRTX
$0.29 +$0.01 (3.41%) After hours
HERON THERAPEUTICS, INC. logo

HERON THERAPEUTICS, INC.

herontx.com

What Do They Do?

Sells CINVANTI, an intravenous medicine for preventing chemotherapy-related nausea and vomiting, and medicines for postsurgical pain and nausea to specialty distributors and wholesalers serving hospitals and healthcare providers.

How Do They Make Money?

CINVANTI is the largest product by revenue; Heron sells its medicines to specialty distributors and full-line wholesalers and gets paid when products are delivered.

revenue
SegmentShareRevenue
CINVANTI
Sold outright

62%
FY2022: 81%
ZYNRELEF
Sold outright

25%
FY2022: 9.5%
APONVIE
Sold outright
7.5%
SUSTOL
Sold outright
5.5%
FY2022: 9.5%

Who Are Their Customers?

Heron sells to a limited number of specialty distributors and full-line wholesalers, which resell the medicines to healthcare providers and hospitals.

Do Revenues Turn Into Profits?

No. It lost $20.2M in FY2025.

Operating income, FY2025
−2% of revenue
▲ +78% (Loss) vs FY2024 (−$11.5M, −8%)
Net income, FY2025
−13% of revenue
▼ −49% (Loss) vs FY2024 (−$13.6M, −9%)
Free cash flow, FY2025
−18% of revenue
▼ −15% (Loss) vs FY2024 (−$24.2M, −17%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −8%
vs $38.2M in Q3 FY2025
Net income
▲ +71% (Loss)
vs −$17.5M in Q3 FY2025
CINVANTI share of revenue vs 62.7% in Q3 FY2025
  • Nov 9, 2026 Withdrew 2026 financial guidance Heron said it is not providing financial guidance at this time.
  • Nov 8, 2026 Agreed to sell substantially all assets to CorMedix The transaction remains subject to Heron stockholder approval and other closing conditions and is expected to close in the first quarter of 2027.
  • Sep 23, 2026 Licensed rights to distribute and sell additional products The agreement provides for development and commercialization collaboration in the United States.

Growing. Revenue grew 79% in 4 years, from $86.3M in FY2021 to $154.9M in FY2025, about 16% a year.

SUSTOL commercialization The latest report says Heron plans to wind down SUSTOL commercialization while evaluating product updates; the older report described SUSTOL as a marketed oncology product.

ZYNRELEF indication The latest report describes ZYNRELEF for soft-tissue and orthopedic procedures, whereas the older report listed a narrower set of specific surgeries.

Revenue over time
CINVANTI ZYNRELEF APONVIE SUSTOL
$200M$100M$0

Who Do They Compete With?

Competes with Pfizer, Fresenius Kabi USA, Pacira BioSciences, Innocoll Pharmaceuticals, Durect, Baudax Bio, Mallinckrodt Pharmaceuticals, Kowa Pharmaceuticals America, Eagle Pharmaceuticals, Takeda Pharmaceutical, Merck &, Helsinn Therapeutics (U.S.), TerSera Therapeutics, Amneal Pharmaceuticals, Cumberland Pharmaceuticals, GlaxoSmithKline, Hoffman-La Roche, Eisai, Helsinn Healthcare, and AVYXA

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support